Anne Elisabeth Carvalho Jensen

This inventor holds 21 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Anti-IL-6 Antibodies. Top assignees: Alderbio Holdings LLC, Vitaeris Inc.. Active years: 2011-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anne Elisabeth Carvalho Jensen. Retrieved from https://idiyas.com/inventor/anne-elisabeth-carvalho-jensen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 21 (Patent Applications = 10)

% Patents Active = 47.6

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 7.9

ph-index = 8

Forward Citations = 297(Granted Patents)

Location History:

Edmonds, WA (US) (2011 - 2017)
Snohomish, WA (US) (2017 - 2020)
Wenatchee, WA (US) (2018 - 2021)
Mill Creek, WA (US) (2019 - 2023)

Company Filing History:

18 out of 98

Alderbio Holdings LLC

Years Active: 2011-2023

Loading Chart...

Areas of Expertise:

Anti-IL-6 Antibodies

Autoimmunity

Chronic Diseases

Asthma Treatment

Nucleic Acids

Isolated Host Cells

Epitopic Specificity

Diagnostic Methods

Composition Development

Recombinant Production

Therapeutic Use

Disease Prevention

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11827700 - Treatment or prevention of diseases and disorders associated with cells that express IL-6 with Anti-IL-6 antibodies (2023-11-28),

2. 10913794 - Antibodies to IL-6 and use thereof (2021-02-09),

3. 10800841 - Methods of treating autoimmunity using specific anti-IL-6 antibodies (2020-10-13),

4. 10759853 - Antibodies to IL-6 and use thereof (2020-09-01),

5. 10391169 - Method of treating allergic asthma with antibodies to IL-6 (2019-08-27),

6. 10344086 - Antibodies to IL-6 and use thereof (2019-07-09),

7. 10233239 - Isolated host cells expressing anti-IL-6 antibodies (2019-03-19),

8. 10117955 - Methods of aiding in the diagnosis of diseases using anti-IL-6 antibodies (2018-11-06),

9. 9890214 - Antibodies to TNF α and use thereof (2018-02-13),

10. 9884912 - Antibodies to IL-6 and use thereof (2018-02-06),

11. 9879074 - Antibodies to IL-6 and use thereof (2018-01-30),

12. 9775921 - Subcutaneously administrable composition containing anti-IL-6 antibody (2017-10-03),

13. 9771421 - Treating anemia in chronic IL-6 associated diseases using anti-IL-6 antibodies (2017-09-26),

14. 9758579 - Nucleic acids encoding anti-IL-6 antibodies of defined epitopic specificity (2017-09-12),

15. 9725509 - Expression vectors containing isolated nucleic acids encoding anti-human IL-6 antibody (2017-08-08),

Title: Innovator Spotlight: Anne Elisabeth Carvalho Jensen

Introduction: Anne Elisabeth Carvalho Jensen is a distinguished inventor based in Edmonds, WA, renowned for her contributions to the field of biomedical research. With an impressive portfolio of 21 patents, her work primarily focuses on the treatment and prevention of diseases associated with the interleukin-6 (IL-6) pathway.

Latest Patents: Among her latest innovations, Jensen has developed patents involving antibodies and fragments that specifically bind to IL-6. These inventions encompass humanized versions of antibodies targeting IL-6, which are crucial in diagnosing and treating various IL-6 related disorders. Jensen's patents detail methods for producing these antibodies and their conjugates, enhancing the ability to leverage these treatments in clinical applications. Furthermore, her work addresses the mechanisms by which these antibodies inhibit the biological effects associated with IL-6, including its interactions with IL-6 receptors.

Career Highlights: Over her impressive career, Anne has made significant strides in the biotechnology sector. She has contributed to the advancement of therapeutic strategies that take aim at IL-6, a cytokine involved in inflammatory responses. During her time at Alderbio Holdings LLC and Vitaeris Inc., she has worked to transition her scientific discoveries from the lab into potential treatments for patients.

Collaborations: Jensen's innovative endeavors have been supported by collaborations with respected colleagues in the field. Notable coworkers such as Leon F Garcia-Martinez and John A Latham have contributed to her research, enabling a productive exchange of ideas and expertise.

Conclusion: Anne Elisabeth Carvalho Jensen exemplifies the spirit of innovation with her extensive body of work focused on IL-6 antibodies. As a successful inventor, her contributions have the potential to significantly impact the landscape of disease treatment and prevention, marking her as a key figure in the biotechnology community. Her patents not only reflect her creativity and scientific acumen but also hold promise for future medical advancements.

Profile summary based on public USPTO records.